Bio Essence Corporation Expands MediFlow Platform with Development of Practitioner-Specific AI and RAG Technology

Bio Essence will own the developed technology, with limited rights applying to approved third-party and pre-existing components.

Rhea-AI Summary

Bio Essence (BIOE) has signed a technology development agreement with Zhituo Software to add practitioner-focused artificial intelligence to MediFlow.

The initiative follows Bio Essence's completed acquisition of the MediFlow AI platform from Zhituo. It is designed to let authorized practitioners create private AI assistants using their own authorized professional materials. Development includes retrieval-augmented generation (RAG), which uses stored materials to inform AI responses. Bio Essence will own the developed technology and related intellectual property, subject to limited rights for approved third-party and pre-existing components. Completion and delivery are scheduled for December 15, 2026, subject to Bio Essence's testing and acceptance procedures.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Signed development agreement with Zhituo adds planned practitioner-focused AI capabilities to MediFlow.
• Moderate pointMediFlow AI platform acquisition from Zhituo is completed.
• Minor point. Forward-looking: it has not happened yet and may not happen.Developed technology and related intellectual property will be owned by Bio Essence.
• Minor point. Forward-looking: it has not happened yet and may not happen.Completion and delivery are currently scheduled for December 15, 2026.

Negative

• Minor pointTechnology ownership is subject to limited rights for approved third-party and pre-existing components.
• Minor point. Forward-looking: it has not happened yet and may not happen.Development delivery remains subject to Bio Essence's testing and acceptance procedures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, CA / ACCESS Newswire / October 15, 2026 / Bio Essence Corporation (OTCQB:BIOE) ("Bio Essence" or the "Company") today announced that it has entered into a technology development agreement with Zhituo Software Co., Limited ("Zhituo") to develop and integrate practitioner-focused artificial intelligence and retrieval-augmented generation ("RAG") capabilities into Bio Essence's MediFlow platform.

The initiative is designed to enable authorized healthcare and wellness practitioners to create private AI assistants using their own authorized professional materials, such as protocols, formulas, educational content and case-derived knowledge.

Following the completion of its previously announced acquisition of the MediFlow AI platform from Zhituo, Bio Essence is advancing a new development initiative focused on practitioner-specific AI capabilities within MediFlow.

Building Practitioner-Centered AI Infrastructure

Key Agreement Details:

• Development Scope: The agreement covers development of a secure Practitioner Knowledge Vault, RAG technology, practitioner-specific AI agents, source provenance, role-based access controls, tenant isolation, audit logging, model orchestration and configurable safety controls.
• Technology Ownership: Under the development agreement, the developed technology, including source code, RAG pipelines, AI workflows, APIs, configurations and related intellectual property, will be owned by Bio Essence, subject to limited rights relating to approved third-party and pre-existing components.
• Development Timeline: The development program is currently scheduled for completion and delivery by December 15, 2026, subject to Bio Essence's testing and acceptance procedures.

Management Commentary

"Our vision for MediFlow is to give practitioners intelligent technology that helps them organize and utilize their own professional knowledge while keeping practitioners at the center of professional decision-making," said Yin Yan, Chief Executive Officer and Chair of the Board of Directors of Bio Essence Corporation. "We believe practitioner-specific AI represents an important next step in our strategy to build a broader technology-enabled healthcare ecosystem."

About Bio Essence Corporation

Bio Essence Corporation (OTCQB:BIOE) is developing a technology-enabled healthcare ecosystem intended to connect practitioners, patients, laboratories, pharmacies, wellness providers and health brands. Through MediFlow and its developing AI capabilities, Bio Essence is seeking to create infrastructure that enables healthcare and wellness practitioners to integrate professional knowledge, workflow tools and AI-assisted technology within a unified platform.

About Zhituo Software Co., Limited

Zhituo Software Co., Limited is a Hong Kong-based software development company specializing in innovative health data management and AI-driven technical frameworks.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding the development, functionality, integration, testing, completion, commercialization, adoption and potential benefits of MediFlow and the Practitioner AI Platform, as well as Bio Essence's business plans and future opportunities. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. There can be no assurance that development milestones will be completed on schedule, that anticipated functionality will be achieved, that pilot or commercial adoption will occur, or that the platform will achieve any particular commercial, financial or regulatory outcome. Bio Essence undertakes no obligation to update forward-looking statements except as required by law.

Investor Relations / Media Contact:
Name: Bill Sluss
Title: CFO
Email: legal@bioessence.com Phone: 1-888-816-1494
Website: https://www.bioessencecorp.com/

SOURCE: Bio Essence Corporation

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bio Essence's MediFlow development agreement with Zhituo cover?

The agreement covers practitioner-focused AI and retrieval-augmented generation capabilities for MediFlow. The initiative is designed to let authorized healthcare and wellness practitioners create private AI assistants using their own authorized professional materials, including protocols, formulas, educational content and case-derived knowledge.

When is Bio Essence's MediFlow AI development scheduled for delivery?

Completion and delivery are currently scheduled for December 15, 2026, subject to Bio Essence's testing and acceptance procedures.

What access and oversight controls are included in Bio Essence's MediFlow development agreement?

The development scope includes role-based access controls, tenant isolation and audit logging. It also covers a secure Practitioner Knowledge Vault, source provenance to track information origins, and configurable safety controls. These are development commitments, not a statement that the capabilities are already deployed.